Duchenne Muscular Dystrophy Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030
Duchenne muscular dystrophy is a genetic disorder which causes progressive muscle degeneration and weakness, and it is one of the nine types of muscular dystrophy. Duchenne muscular dystrophy mostly affects males, but in rare cases occurs in females. Onset of the disease is generally 3 to 4 years of age and begins on hips, pelvic region, shoulders, and upper legs. Symptoms may include delayed or difficulty inability to stand, walk and difficulty in speaking.
Disease is diagnosed through the patient history, blood test for creatinine phosphokinase levels, molecular genetic testing, and muscle biopsy. There is no cure available for the disease till now. But the medications are available forrelieving the symptoms of the disease. Eteplirsen is used to treat the patients with specific gene mutation of gene that leads to DMD. Deflazacort, approved in 2017, becoming first corticosteroid to treat Duchenne muscular dystrophy.
Key Developments:
Duchenne Muscular Dystrophy Pipeline Drugs Assessment report studies the various therapeutics under clinical development for XYX treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Duchenne muscular dystrophy pipeline drugsdevelopment. This report studies the dynamics of the Duchenne Muscular Dystrophy Pipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Duchenne muscular dystrophy pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
|
Report Benchmarks |
Details |
|
By formulation |
|
|
By therapy |
|
|
By trial phase |
|
|
By company |
|
Download Free Sample Report
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
